We are international
Donate
TEXT SIZE   

NINLARO (ixazomib) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma.

Ixazomib was granted orphan drug designation in MM in both the U.S. and Europe in 2011, and for AL amyloidosis in both the U.S. and Europe in 2012. Ixazomib received Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for relapsed and/or refractory AL amyloidosis in 2014. It is also the first oral proteasome inhibitor to enter Phase 3 clinical trials.

Four global Phase 3 trials are ongoing: TOURMALINE-MM1, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in relapsed and/or refractory MM; TOURMALINE-AL1, investigating ixazomib plus dexamethasone in patients with relapsed or refractory AL amyloidosis; TOURMALINE-MM2, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in patients with newly diagnosed MM; and TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed MM following induction therapy and autologous stem cell transplant.

For additional information on the ongoing Phase 3 studies please visit www.clinicaltrials.gov.

For more information about NINLARO please visit www.NINLARO.com

General Information
Clinical Trials
Webcasts
International Clinical Trial Fact Sheets
News & Press Releases
Ninlaro Video

Understanding Ninlaro®

Ninlaro is the first oral proteasome inhibitor approved by the FDA to treat multiple myeloma. It is the third drug in the proteasome inhibitor class that has been approved for MM. Ninlaro is indicated for myeloma patients who have received at least one prior therapy. 


NINLARO 1Point
NINLARO 1Point offers comprehensive programs that can assist with the financial burden and other day-to-day needs associated with your NINLARO® (ixazomib) treatment.

NINLARO® (ixazomib) Prescribing Information
Highlights of prescribing information. These highlights do not include all the information needed to use NINLARO safely and effectively.

NINLARO® (ixazomib) website
General information about NINLARO® (ixazomib)

Proteasome Inhibitors in Clinical Trials
Conversations with Dr. Robert Orlowski and Dr. Sagar Lonial regarding Proteasome Inhibitors in Clinical Trials.